• Molecular NameMethylphenobarbital
  • SynonymMephobarbital; Mephobarbitone; Methyl Phenobarbitone; Methylphenobarbitalum [INN-Latin]; Methylphenobarbitonum; Methylphenolbarbital; Methylphenylbarbituric acid; Metilfenobarbital [INN-Spanish]; Metilfenobarbitale [Dcit]; N-Ethylmethylphenylbarbituric acid; N-Methylethylphenylbarbituric acid; N-Methylphenobarbital; N-Methylphenolbarbitol
  • Weight246.266
  • Drugbank_IDDB00849
  • ACS_NO115-38-8
  • Show 3D model
  • LogP (experiment)1.84
  • LogP (predicted, AB/LogP v2.0)1.89
  • pka7.8
  • LogD (pH=7, predicted)1.86
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-2.14
  • LogSw (predicted, AB/LogsW2.0)1.78
  • Sw (mg/ml) (predicted, ACD/Labs)1.61
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds2
  • TPSA66.48
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug which is a barbiturate derivative.
  • Absorption_value50.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding73.0
  • Volume of distribution (VD)2 to 3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, primarily by the hepatic microsomal enzyme system. About 75% of a single oral dose of mephobarbital is metabolized to phenobarbital in 24 hours.
  • Half lifemethylphenobarbital about 50~60 h, phenobarbital about 100 h.
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common adverse reaction estimated to occur at a rate of 1 to 3 patients per 100 is somnolence. Other adverse effects estimated to occur less frequently.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=300